LEXINGTON, Mass. — Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, today announced that the U.S. Food and...
Latest News
NEW YORK — Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company’s Akt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. Abstract #5034, entitled, “Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx)...
East Hanover, NJ – This year, New Jersey Health Foundation (NJHF) granted $135,000 in awards to three Kessler Foundation scientists to support pilot research projects that exhibit promising potential. Foundation researchers will conduct studies that expand research in web-based job interview training for youth on the autism spectrum, upper extremity...
East Hanover, NJ – A research scientist at Kessler Foundation has been awarded a highly competitive Mentored Patient-Oriented Research Career Development Award (K23) from the National Institute on Minority Health and Health Disparities, a part of the National Institutes of Health (NIH). This $704,054, five-year grant will support one of...
East Hanover, NJ – Researchers at Kessler Foundation have published a new clinical protocol examining the combination of aerobic exercise and cognitive rehabilitation to improve learning and memory in individuals with multiple sclerosis (MS) who have mobility disability. The article, “Rationale and methodology for examining the combination of aerobic exercise...
WINNIPEG — Local medical researchers are optimistic they’ve found the key to unlocking a cure for a rare genetic disorder that affects Hutterite babies. Scientists at the University of Manitoba and the Manitoba Institute of Child Health have discovered that a small change in a gene involved in cell growth,...
Melbourne, Australia – The global rise in obesity and diabetes is leading to an epidemic in fatty liver disease affecting 20-30 per cent of the world’s population. Almost a third of people with fatty liver disease go on to develop an advanced form of the disease, known as non-alcoholic steatohepatitis...
CHENGDU, China — Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi’s research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) has recently published a research report titled “BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR...
KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025 during a Plenary Session and included in official meeting press program...
SOUTH SAN FRANCISCO, Calif. – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors. “Micki’s addition to the board is instrumental as we continue to evaluate the...